These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34293596)

  • 21. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-1 blockade improves the anti-tumor potency of exhausted CD3
    Tao L; Wang S; Kang G; Jiang S; Yin W; Zong L; Li J; Wang X
    Oncoimmunology; 2021; 10(1):2002068. PubMed ID: 34777920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
    Yao X; Wang L; Gao J
    Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
    Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
    Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levels of chemokine receptors expressed on peripheral blood T lymphocytes of Egyptian patients with hepatocellular carcinoma.
    Allam MM; Abd El Moneim E; Hassouna MM; El Jaky A; Zaghlah H
    Egypt J Immunol; 2009; 16(1):17-25. PubMed ID: 20726319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression.
    Yun J; Yu G; Hu P; Chao Y; Li X; Chen X; Wei Q; Wang J
    Immunol Res; 2020 Dec; 68(6):436-444. PubMed ID: 32975728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
    Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
    Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
    Lu F; Ma XJ; Jin WL; Luo Y; Li X
    Front Immunol; 2021; 12():690565. PubMed ID: 34054880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
    Tan Z; Chiu MS; Yang X; Yue M; Cheung TT; Zhou D; Wang Y; Chan AW; Yan CW; Kwan KY; Wong YC; Li X; Zhou J; To KF; Zhu J; Lo CM; Cheng AS; Chan SL; Liu L; Song YQ; Man K; Chen Z
    Gut; 2023 Aug; 72(8):1568-1580. PubMed ID: 36450387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
    Shin S; Kim M; Lee SJ; Park KS; Lee CH
    Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
    Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
    Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.
    Su X; Yin H; Bai M; Liu J; Liu R; Zeng H; Wen J
    J Immunol; 2023 Mar; 210(5):681-695. PubMed ID: 36602827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.